Polymorphism and solvatomorphism 2009

Journal of Pharmaceutical Sciences

Volumn 100, Issue 4, 2011, Pages 1260-1279

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

Crystallography; Crystals; Hydrates solvates; Polymorphism; X ray powder diffractometry

Indexed keywords

1,4 DIAZABICYCLO[2.2.2]OCTANE; 4 NITROQUINOLINE 1 OXIDE; AMINOSALICYLIC ACID; ASTAXANTHIN; BARBITURIC ACID; BENZOIC ACID; BETA CYCLODEXTRIN; CABERGOLINE; CARBAPENEM; CARVEDILOL; CHENODEOXYCHOLIC ACID; CHOLIC ACID; CICLOPIROX; CYSTEINE; DEOXYCHOLIC ACID; DONEPEZIL; GLUTAMIC ACID; HYODEOXYCHOLIC ACID; IBANDRONIC ACID; LITHOCHOLIC ACID; MANNITOL; MONTELUKAST; NAFTAZONE; NORLEUCINE; OXYCODONE; RIFAXIMIN; SIMVASTATIN; TRISTEARIN; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; DRUG; SOLVENT;

ARTICLE; BIOTRANSFORMATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG STRUCTURE; GENETIC POLYMORPHISM; HUMAN; SOLVATOMORPHISM; STRUCTURE ANALYSIS; THEORETICAL STUDY; X RAY POWDER DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; PATENT; PROCEDURES;

CRYSTALLIZATION; CRYSTALLOGRAPHY; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; SOLVENTS;

EID: 79951872764     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22386     Document Type: Article

References (232)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs. 2nd ed. West Lafayette: SSCI, Inc.
2. Brittain HG. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
3. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Clarendon Press.
4. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
5. Brittain HG. 2005. Polymorphism and solvatomorphism 2004. In profiles of drug substances, excipients, and related methodology. Brittain HG, Ed. Vol. 32. Amsterdam: Elsevier Academic Press, pp. 263-283.
6. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J Pharm Sci 96:705-728.
7. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J Pharm Sci 97:3611-3636.
8. Brittain HG. 2009. Polymorphism and solvatomorphism 2007. J Pharm Sci 98:1617-1642.
9. Brittain HG. 2010. Polymorphism and solvatomorphism 2008. J Pharm Sci 99:in press.
10. Brittain HG. 2009. Polymorphism in pharmaceutical solids; 2nd ed. New York: Informa Healthcare Press.
11. Galek PTA, Fábián L, Allen FH. 2009. Persistent hydrogen bonding in polymorphic crystal structures. Acta Crystallogr B 65:68-85.
12. Chu KA, Yalkowsky SH. 2009. An interesting relationship between drug absorption and melting point. Int J Pharm 373:24-40.
13. Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. 2009. Solid form screening - A review. Eur J Pharm Biopharm 71:23-37.
14. Sun CC. 2009. Materials science tetrahedron - a useful tool for pharmaceutical research and development. J Pharm Sci 98:1671-1687.
15. Heinz A, Strachan CJ, Gordon KC, Rades T. 2009. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol 61:971-988.
16. Zhou G, Moment A, Cote A, Hu T-E. 2009. Utilizing spectroscopy of the isolation of desired API crystal form. Am Pharm Rev 12(5):62-68.
17. Neumann MA, Perrin M-A. 2009. Can crystal structure prediction guide experimentalists to a new polymorph of paracetamol? Cryst Eng Comm 11:2475-2479.
18. Izgorodina EI, Bernard UL, Dean PM, Pringle JM, MacFarlane DR. 2009. The Madelung constant of organic salts. Cryst Growth Des 9:4834-4839.
19. Galek PTA, Allen FH, Fábián L, Feeder N. 2009. Knowledge-based H-bond prediction to aid experimental polymorph screening. Cryst Eng Comm 11:2634-2639.
20. Surov AO, Terekhova IV, Bauer-Brandl A, Perlovich G. 2009. Thermodynamic and structural aspects of some fenamate molecular crystals. Cryst Growth Des 9:3265-3272.
21. Fayos, J. 2009. Molecular crystal prediction approach by molecular similarity: Data mining on molecular aggregation predictors and crystal descriptors. Cryst Growth Des 9:3142-3153.
22. Kitamura M. 2009. Strategy for control of crystallization of polymorphs. Cryst Eng Comm 11:949-964.
23. Di Profio G, Curcio E, Ferraro S, Stabile S, Drioli E. 2009. Effect of supersaturation control and heterogeneous nucleation on porous membrane surfaces in the crystallization of L-glutamic acid polymorphs. Cryst Growth Des 9:2179-2186.
24. Kudernac T, Sändig N, Landaluce TF, van Wees BJ, Rudolf P, Katsonis N, Zerbetto F, Feringa BL. 2009. Intermolecular repulsion through interfacial attraction: Toward engineering of polymorphs. J Am Chem Soc 131:15655-15659.
25. Zencirci N, Gelbrich T, Kahlenberg V, Griesser UJ. 2009. Crystallization of metastable polymorphs of phenobarbital by isomorphic seeding. Cryst Growth Des 9: 3444-3456.
26. Li H, Yang H, Wang Y, Yuan W, Wang L, Wang G. 2009. Searching for unknown polymorphs by "quenched nucleation": Studies on the polymorphism of N-(1-naphthyl)-succinimide. Cryst Growth Des 9:3817-3820.
27. Singh A, Lee IS, Myerson AS. 2009. Concomitant crystallization of ROY on patterned substrates: Using a high throughput method to improve the chances of crystallization of different polymorphs. Cryst Growth Des 9:1182-1185.
28. Alvarez AJ, Singh A, Myerson AS. 2009. Polymorph screening: Comparing a semi-automated approach with a high throughput method. Cryst Growth Des 9:4181-4188.
29. Page AJ, Sear RP. Crystallization controlled by the geometry of a surface. J Am Chem Soc 131:17550-17551.
30. López-Mejías V, Kampf JW, Matzger AJ. 2009. Polymer-induced heteronucleation of tolfenamic acid: Structural investigation of a pentamorph. J Am Chem Soc 131:4554-4555.
31. Tian F, Baldursdottir S, Rantanen J. 2009. Effects of polymer additives on the crystallization of hydrates: A molecular-level modulation. Mol Pharm 6:202-210.
32. Urbanus J, Laven J, Roelands CPM, ter Horst JH, Verdoes D, Jansens PJ. 2009. Template induced crystallization: A relation between template properties and template performance. Cryst Growth Des 9:2762-2769.
33. Ha J-M, Hamilton BD, Hillmyer MA, Ward MD. 2009. Phase behavior and polymorphism of organic crystals confined within nanoscale chambers. Cryst Growth Des 9:4766-4777.
34. Oswald IDH, Chataigner I, Elphick S, Fabbiani FPA, Lennie AR, Maddaluno J, Marshall WG, Prior TJ, Pulham CR, Smith RI. 2009. Putting pressure on elusive polymorphs and solvates. Cryst Eng Comm 11:359-366
35. Fabbiani FPA, Dittrich B, Florence AJ, Gelbrich T, Hursthouse MB, Kuhs WF, Shankland N, Sowa H. 2009. Crystal structures with a challenge: High-pressure crystallization of ciprofloxacin sodium salts and their recovery to ambient pressure. Cryst Eng Comm 11:1396-1406.
36. Kee NCS, Tan RBH, Braatz RD. 2009. Selective crystallization of the metastable α-form of L-glutamic acid using concentration feedback control. Cryst Growth Des 9:3044-3051.
37. Kee NCS, Arendt PD, Tan RBH, Braatz RD. 2009. Selective crystallization of the metastable anhydrate form in the enantiotropic pseudo-dimorph system of L-phenylalanine using concentration feedback control. Cryst Growth Des 9:3052-3061.
38. Anuar N, Daud WRW, Roberts KJ, Kamarudin SK, Tasirin SM. 2009. An examination of the solution chemistry, nucleation kinetics, crystal morphology, and polymorphic behavior of aqueous phase batch crystallized L-isoleucine at the 250 mL scale size. Cryst Growth Des 9:2853-2862.
39. Thun J, Seyfarth L, Butterhof C, Senker J, Dinnebier RE, Breu J. 2009. Wöhler and Liebig revisited: 176 years of polymorphism in benzamide and the story still continues! Cryst Growth Des 9:2435-2441.
40. Braun DE, Gelbrich T, Kahlenberg V, Tessadri R, Wieser J, Griesser US. 2009. Conformational polymorphism in aripiprazole: Preparation, stability and structure of five modifications. J Pharm Sci 98:2010-2026.
41. Lemmerer A, Bthori NB, Esterhuysen C, Bourne SA, Caira MR. 2009. Concomitant polymorphs of the antihyperlipoproteinemic bezafibrate. Cryst Growth Des 9:2646-2655.
42. Niederwanger V, Gozzo F, Griesser UJ. 2009. Characterization of four crystal polymorphs and a monohydrate of s-bupivacaine hydrochloride (levobupivacaine hydrochloride). J Pharm Sci 98:1064-1074.
43. Chan EJ, Welberry TR, Goossens DJ, Heerdegen AP, Beasley AG, Chupas PJ. 2009. Single-crystal diffuse scattering studies on polymorphs of molecular crystals. I. The room-temperature polymorphs of the drug benzocaine. Acta Crystallogr B 65:382-392.
44. Chan EJ, Rae AD, Welberry TR. 2009. On the polymorphism of benzocaine; a low-temperature structural phase transition for form (II). Acta Crystallogr B 65:509-515.
45. Martins FT, Bocelli MD, Bonfilio R, de Arajo MB, de Lima PV, Neves PP, Veloso MP, Ellena J, Doriguetto AC. 2009. Conformational polymorphism in racemic crystals of the diuretic drug chlortalidone. Cryst Growth Des 9:3235-3244.
46. Német Z, Pokol G, Demeter A. 2009. Quantifying low levels of polymorphic impurity in clopidogrel bisulphate by vibrational spectroscopy and chemometrics. J Pharm Biomed Anal 49:32-41
47. Baronsky J, Bongaerts S, Traeubel M, Weiss H-C, Urbanetz N. 2009. The study of different solid forms of Emodepside. Eur J Pharm Biopharm 71:88-99.
48. Német Z, Kis GC, Pokol G, Demeter A. 2009. Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study. J Pharm Biomed Anal 49:338-346.
49. Lou B, Bostrm D, Velaga SP. 2009. Polymorph control of felodipine form II in an attempted cocrystallization. Cryst Growth Design 9:1254-1257.
50. Heinz A, Gordon KC, McGoverin CM, Rades T, Strachan CJ. 2009. Understanding the solid-state forms of fenofibrate - A spectroscopic and computational study. Eur J Pharm Biopharm 71:100-108.
51. Aceves-Hernandez JM, Nicolás-Vázquez I, Aceves FJ, Hinojosa-Torres J, Paz M, Castaño VM. 2009. Indomethacin polymorphs: Experimental and conformational analysis. J Pharm Sci 98:2448-2463.
52. Felipe T. Martins, Person P. Neves, Javier Ellena, Gerardo E. Camí, Elena V. Brusau, Griselda E. Narda. 2009. Intermolecular contacts influencing the conformational and geometric features of the pharmaceutically preferred mebendazole polymorph C. J Pharm Sci 98:2336-2344.
53. Bruni G, Berbenni V, Milanese C, Girella A, Cardini A, Viganò E, Lanfranconi S, Marini A. 2009. Thermodynamic relationships between nateglinide polymorphs. J Pharm Biomed Anal 50:764-770.
54. Barrio M, Espeau P, Tamarit JL, Perrin M-A, Veglio N, Ceolin R. 2009. Polymorphism of progesterone: Relative stabilities of the orthorhombic phases I and II inferred from topological and experimental pressure-temperature phase diagrams. J Pharm Sci 98:1657-1670.
55. de Armas HN, Peeters OM, Blaton N, van Gyseghem E, Martens J, van Haele G, Van Den Mooter G. 2009. Solid state characterization and crystal structure from X-ray powder diffraction of two polymorphic forms of ranitidine base. J Pharm Sci 98:146-158.
56. Chieng N, Rehder S, Saville D, Rades T, Aaltonen J. 2009. Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. J Pharm Biomed Anal 49:18-25.
57. Surov AO, Szterner P, Zielenkiewicz W, Perlovich GL. 2009. Thermodynamic and structural study of tolfenamic acid polymorphs. J Pharm Biomed Anal 50:831-840.
58. van Eupen JTH, Westheim R, Deij MA, Meekes H, Bennema P, Vlieg E. 2009. The solubility behavior and thermodynamic relations of the three forms of Venlafaxine free base. Int J Pharm 368:146-153.
59. Portell A, Barbas R, Font-Bardia M, Dalmases P, Prohens R, Puigjaner C. 2009. Ziprasidone malate, a new trimorphic salt with improved aqueous solubility. Cryst Eng Comm 11:791-795.
60. Katrincic LM, Sun YT, Carlton RA, Diederich AM, Mueller RL, Vogt FG. 2009. Characterization, selection, and development of an orally dosed drug polymorph from an enantiotropically related system. Int J Pharm 366:1-13.
61. Li H, Kiang Y-H, Jona J. 2009. Multiple approaches to pharmaceutical polymorphism investigation - A case study. Eur J Pharm Sci 38:426-432.
62. Nassimbeni LR, Ramon G, Taljaard JH. 2009. Selectivity profiles of 5-(4-methoxyphenyl)-5H-di benzo[a, d]cyclohepten-5-ol with aromatic solvents and conformational polymorphism of 10, 11-dihydro-5-(4-methoxyphenyl)-5H-dibenzo[a, d]cyclohepten-5-ol. Cryst Growth Des 9:88-94.
63. Gao Y-H, Zhou W, Li L, Wu J-Y, Zhou H-P, Yang J-X, Tian Y-P. 2009. Polymorphism in a highly conjugated organic compound: Strong photoelectric response. Cryst Growth Des 9:253-257.
64. Hisaki I, Sakamoto Y, Shigemitsu H, Tohnai N, Miyata M. 2009. Conformational polymorphism of octadehydrodibenzo[12]annulene with dimethyl phthalate moieties. Cryst Growth Des 9:414-420.
65. MacLean EJ, Tremayne M, Kariuki BM, Cameron JRA, Roberts MA, Harris KDM. 2009. Lessons on the discovery and assignment of polymorphs, highlighted by the case of the latent pigment DPP-Boc. Cryst Growth Des 9:853-857.
66. Fan Y, Zhao Y, Ye L, Li B, Yang G, Wang Y. 2009. Polymorphs and pseudopolymorphs of N, N-di(n-butyl)quinacridone: Structures and solid-state luminescence properties. Cryst Growth Des 9:1421-1430.
67. Dureisseix V, Sanselme M, Robin Y, Coquerel G. 2009. Two Concomitant polymorphs of 1, 2-naphthoquinone-2-semicarbazone. Cryst Growth Des 9:3438-3443.
68. Reany O, Kapon M, Botoshansky M, Keinan E. 2009. Rich polymorphism in triacetone-triperoxide. Cryst Growth Des 9:3661-3670.
69. Adam-Berret M, Riaublanc A, Rondeau-Mouro C, Mariette F. 2009. Effects of crystal growth and polymorphism of triacylglycerols on NMR relaxation parameters. 1. Evidence of a relationship between crystal size and spin-lattice relaxation time. Cryst Growth Des 9:4273-4280.
70. Adam-Berret M, Riaublanc A, Mariette F. 2009. Effects of crystal growth and polymorphism of triacylglycerols on NMR relaxation parameters. 2. Study of a tricaprin-tristearin mixture. Cryst Growth Des 9:4281-4288.
71. Nonappa N, Lahtinen M, Ikonen S, Kolehmainen E, Kauppinen R. 2009. Solid-state NMR, X-ray diffraction, and thermoanalytical studies towards the identification, isolation, and structural characterization of polymorphs in natural bile acids. Cryst Growth Des 9:4710-4719.
72. Portell A, Barbas R, Braga D, Polito M, Puigjaner C, Prohens R. 2009. New polymorphic hydrogen bonding donor-acceptor system with two temperature coincident solid-solid transitions. Cryst Eng Comm 11:52-54.
73. Kirchner MT, Bläser D, Boese R, Desiraju GR. 2009. Additive induced polymorphism. The pentafluorophenol-pentafluoroaniline system. Cryst Eng Comm 11:229-231.
74. Raatikainen K, Rissanen K. 2009. Hierarchical halogen bonding induces polymorphism. Cryst Eng Comm 11:750-752.
75. Manoj K, Gonnade RG, Bhadbhade MM, Shashidhar MS. 2009. Isostructural molecular strings linked via conserved dipolar (ether) OCO short contacts in conformational polymorphs of racemic 2, 4-di-O-acetyl-6-O-tosyl-myo-inositol 1, 3, 5-orthoesters. Cryst Eng Comm 11:1022-1029.
76. Imai Y, Kinuta T, Nagasaki K, Harada T, Sato T, Tajima N, Sasaki Y, Kuroda R, Matsubara Y. 2009. Conformational and color polymorphism of achiral 2-methyl-3-(2-naphthalenylthio)-1, 4-naphthalenedione. Cryst Eng Comm 11:1223-1226.
77. Fan Y, Song W, Yu D, Ye K, Zhang J, Wang Y. 2009. Polymorphs and luminescent properties of a cetyl substituted quinacridone derivative. Cryst Eng Comm 11:1716-1722.
78. Nizhnik YP, Lu J, Rosokha SV, Kochi JK. 2009. Trimorphism of a model carcinogen 4-nitroquinoline-N-oxide. Cryst Eng Comm 11:2400-2405.
79. Ivashevskaya SN, van de Streek J, Djanhan JE, Brüning J, Alig E, Bolte M, Schmidt MU, Blaschka P, Höffken HW, Erk P. 2009. Structure determination of seven phases and solvates of pigment yellow 183 and pigment yellow 191 from X-ray powder and single-crystal data. Acta Crystallogr B 65:212-222.
80. Shishkina SV, Zubatyuk RI, Kucherenko LI, Mazur IA, Shishkin OV. 2009. Two polymorphs of morpholin-4-ium 2-(5-methyl-1H-1, 2, 4-triazol-3-ylsulfanyl)acetate. Acta Crystallogr C 65:o24-o26.
81. Khrustalev VN, Borisova IV, Zemlyansky NN, Antipin MY. 2009. A new polymorph of triphenylmethylamine: the effect of hydrogen bonding. Acta Crystallogr C 65:o31-o34.
82. Krishnaswamy S, Gonnade RG, Bhadbhade MM, Shashidhar MS. 2009. Two modes of O-HO hydrogen bonding utilized in dimorphs of racemic 6-O-acryloyl-2-O-benzoyl-myo-inositol 1, 3, 5-orthoformate. Acta Crystallogr C 65:o54-o57.
83. Hori K, Kouno K. 2009. Two crystal forms of mesogenic bis(4'-cyanobiphenyl-4-yl) butanedioate. Acta Crystallogr C 65:o108-o110.
84. Aguilar JAG, Bernès S. 2009. Dimorphic forms of 3, 6-dinitrodurene in a single space group. Acta Crystallogr C 65:o176-o178.
85. Jones PG, Mangalagiu II. 2009. Concomitant polymorphism and conformational isomerism in 4-acetylresorcinol. Acta Crystallogr C 65:o300-o302.
86. Omondi B, Levendis DC, Layh M, Fernandes MA. 2009. Two polymorphs of N-(2, 6-difluorophenyl)formamide. Acta Crystallogr C 65:o470-474.
87. Callear SK, Hursthouse MB. 2009. A new polymorph of 2-methyl-6-nitroaniline. Acta Crystallogr C 65:o539-o542.
88. Nallasivam A, Nethaji M, Vembu N, Jaswant B, Sulochana N. 2009. Dimethyl 2, 2'-[(4-oxo-2-phenyl-4H-chromene-5, 7-diyl)dioxy]diacetate: a more densely packed polymorph. Acta Crystallogr E 65:o312-o313.
89. Nallasivam A, Nethaji M, Vembu N, Jaswant B, Sulochana N. 2009. Dimethyl 2, 2'-[(4-oxo-2-phenyl-4H-chromene-5, 7-diyl)dioxy]diacetate: a less densely packed polymorph. Acta Crystallogr E 65:o314-o315.
90. Shahwar D, Tahir MN, Khan MA, Ahmad N, Furqan M. 2009. 1, 3-bis(3-methylphenyl)thiourea: triclinic polymorph. Acta Crystallogr E 65:o482.
91. El Ashry ESH, Amer MR, Shah MR, Ng SW. 2009. Benzyl 2-(4-bromoanilino)-4, 4-dimethyl-6-oxocyclohex-1-enecarbodithioate: First triclinic polymorph. Acta Crystallogr E 65:o597.
92. El Ashry ESH, Amer MR, Shah MR, Ng SW. 2009. Benzyl 2-(4-bromoanilino)-4, 4-dimethyl-6-oxocyclohex-1-enecarbodithioate: Second triclinic polymorph. Acta Crystallogr E 65:o598.
93. Fun H-K, Chantrapromma S. 2009. A triclinic polymorph of hexanedioic acid. Acta Crystallogr E 65:o624.
94. Izotova LY, Ashurov JM, Ibragimov BT, Weber E. 2009. A new polymorph of N-phenylphthalimide. Acta Crystallogr E 65:o658.
95. Fun H-K, Kia R, Kargar H, Jamshidvand A. 2009. A second tricilinc polymorph of 6, 6'-diethoxy-2, 2'-[propane-1, 2-diylbis(nitrilomethylidyne)]diphenol. Acta Crystallogr E 65:o722-o723.
96. Shao X, Asahi K, Yamauchi T, Sugimoto Y, Shiro M. 2009. A new crystal phase of N, N, N', N'-tetraphenyl-1, 1'-biphenyl-4, 4'-diamine. Acta Crystallogr E 65:o1224.
97. Singh SP, Verdu MJ, Lough AJ, Schwan AL. 2009. Monoclinic modification of N-[(1, 1-dimethylethoxy)carbonyl]-3-[(R)-prop-2-en-1-ylsulfinyl]-(R)-alanine ethyl ester at 200 K. Acta Crystallogr E 65:o1385-o1386.
98. Singh SP, Verdu MJ, Lough AJ, Schwan AL. 2009. Triclinic modification of N-[(1, 1-dimethylethoxy)carbonyl]-3-[(R)-prop-2-en-1-ylsulfinyl]-(R)-alanine ethyl ester at 120 K. Acta Crystallogr E 65:o1387.
99. Yan Y, Mague JT, Donahue JP. 2009. A polymorph of tetraethylammonium chloride. Acta Crystallogr E 65:o1491.
100. Ng SW. 2009. Orthorhombic modification of (E)-4-benzylidene-2-phenyl-1, 3-oxazol-5(4H)-one: whole molecule disorder. Acta Crystallogr E 65:o1857.
101. Jasinski JP, Butcher RJ, Veena K, Narayana B, Yathirajan HS. 2009. A second polymorph of (2E)-1-(4-fluorophenyl)-3-(3, 4, 5-trimethoxyphenyl)prop-2-en-1-one. Acta Crystallogr E 65:o1965-o1966.
102. Fun H-K, Liew W-C, Rai S, Shetty P, Isloor AM. 2009. An orthorhombic polymorph of 6-deoxy-6-iodo-1, 2:3, 4-di-O-isopropylidene-α-D-galactopyranoside. Acta Crystallogr E 65:o1999-o2000.
103. Mamada M, Yamashita Y. 2009. Triclinic polymorph of dibenzotetrathiafulvalene. Acta Crystallogr E 65:o2083.
104. Zhang Y-W, Wang J-, Cheng L. 2009. A second orthorhombic polymorph of 3, 5-diphenyl-4H-1, 2, 4-triazol-4-amine. Acta Crystallogr E 65:o2261.
105. Khan IU, Sharif S, Arshad MN, Ejaz S, Idrees M. 2009. (2R)-2-Benzenesulfonamido-2-phenylethanoic acid: A new monoclinic polymorph. Acta Crystallogr E 65:o2436.
106. Khaledi H, Saharin SM, Ali HM, Robinson WT, Abdulla MA. 2009. A second monoclinic polymorph of 2-(diformylmethylidene)-3, 3-dimethyl-2, 3-dihydro-1H-indole. Acta Crystallogr E 65:o2585.
107. Baul TSB, Kundu S, Arman HD, Tiekink ERT. 2009. An orthorhombic polymorph of 5-[(4-methylphenyl)diazenyl]salicylaldehyde. Acta Crystallogr E 65:o3061.
108. Arman HD, Poplaukhin P, Tiekink ERT. 2009. 2-pyridone: monoclinic polymorph. Acta Crystallogr E 65:o3187.
109. Asnani M, Vyas K, Bhattacharya A, Devarakonda S, Chakraborty S, Mukherjee AK. 2009. Ab initio structure determination of anhydrous sodium alendronate from laboratory powder X-ray diffraction data. J Pharm Sci 98:2113-2121.
110. Braun DE, Gelbrich T, Kahlenberg V, Tessadri R, Wieser J, Griesser UJ. 2009. Stability of solvates and packing systematics of nine crystal forms of the antipsychotic drug aripiprazole. Cryst Growth Des 9:1054-1065.
111. 13C CPMAS NMR study of its anhydrous and solvated forms. Cryst Growth Des 9:517-524.
112. Duggirala NK, Kanniah SL, Muppidi VK, Thaimattam R, Devarakonda S. 2009. Polytypism in desvenlafaxine succinate monohydrate. Cryst Eng Comm 11:989-992.
113. Schultheiss N, Smit JP, Hanko JA. 2009. Three isostructural solvates of finasteride and their solid-state characterization. Eur J Pharm Sci 38:498-503.
114. Suitchmezian V, Jess I, Näther C. 2009. Investigations on the desolvation reaction of pseudopolymorphic forms of hydrocortisone. Cryst Growth Des 9:774-782.
115. Ravikumar K, Sridhar B. 2009. Lenalidomide, an antineoplastic drug, and its hemihydrate. Acta Crystallogr C 65:o502-o505.
116. Murakami FS, Lang KL, Mendes C, Cruz AP, Filho MASC, Silva MAS. 2009. Physico-chemical solid-state characterization of omeprazole sodium: Thermal, spectroscopic and crystallinity studies. J Pharm Biomed Anal 49:72-80.
117. Kiang Y-H, Yang C-Y, Staples RJ, Jona J. 2009. Crystal structure, crystal morphology, and surface properties of an investigational drug. Int J Pharm 368:76-82.
118. Zhao XS, Siepmann I, Xu W, Kiang Y-H, Sheth AR, Karaborni S. 2009. Exploring the formation of multiple layer hydrates for a complex pharmaceutical compound. J Phys Chem B 113:5929-5937.
119. Kiang Y-H, Xu W, Stephens PW, Ball RG, Yasuda N. 2009. Layered structure and swelling behavior of a multiple hydrate-forming pharmaceutical compound. Cryst Growth Des 9:1833-1843.
120. Katagiri K, Kato T, Masu H, Tominaga M, Azumaya I. 2009. Pseudopolymorph and infinite hydrogen bonding network of cyclic oligomers of m-aminobenzenesulfonic acid. Cryst Growth Des 9:1519-1224.
121. Li Y, Li L, Zhu Y, Meng X, Wu A. 2009. Solvent effect on pseudopolymorphism of hemicyclohexylcucurbit[6]uril. Cryst Growth Des 9:4255-4257.
122. Kumar TL, Vishweshwar P, Babu JM, Vyas K. 2009. Salts of hydrates of imiquimod, an immune response modifier. Cryst Growth Des 9:4822-4829.
123. Andr V, Braga D, Grepioni F, Duarte MT. 2009. Crystal forms of the antibiotic 4-aminosalicylic acid: Solvates and molecular salts with dioxane, morpholine, and piperazine. Cryst Growth Des 9:5108-5116.
124. Haynes DA, Weng ZF, Jones W, Motherwell WDS. 2009. The crystal structures of three novel lutidinium pamoate salts. Cryst Eng Comm 11:254-260.
125. Nguyen VT, Bishop R, Craig DC, Scudder ML. 2009. Alternative crystal forms produced by a dialcohol inclusion host: Resolutions and polymorphs, part 3. Cryst Eng Comm 11:1275-1280.
126. Nauha E, Saxell H, Nissinen M, Kolehmainen E, Schäfer A, Schlecker R. 2009. Polymorphism and versatile solvate formation of thiophanate-methyl. Cryst Eng Comm 11:2536-2547.
127. Singh D, Baruah JB. 2009. Different solvates of two isomeric dicarboxylic acids with pyridine and quinoline. Cryst Eng Comm 11:2688-2694.
128. Qi D-Q, Hou G-G, Ma J-P, Huang R-Q, Dong Y-B. 2009. A novel three-dimensional framework constructed by 2-[(1H-imidazol-1-yl)methyl]-1H-benzimidazole and infinite chains of hydrogen-bonded water molecules. Acta Crystallogr C 65:o85-o87.
129. Smith G, Wermuth UD, Sagatys DS. 2009. Unusual hydrate stabilization in the two-dimensional layered structure of quinacrinium bis(2-carboxy-4, 5-dichlorobenzoate) tetrahydrate, a proton-transfer compound of the drug quinacrine. Acta Crystallogr C 65:o131-o133.
130. Brüning J, Bolte M, Schmidt MU. 2009. Three solvates of a bis-mesoionic fluorescent yellow pigment. Acta Crystallogr C 65:o352-o356.
131. Langes C, Gelbrich T, Griesser UJ, Kahlenberg V. 2009. Codeine dihydrogen phosphate hemihydrate. Acta Crystallogr C 65:o419-o422.
132. Tutughamiarso M, Bolte M, Egert E. 2009. New pseudopolymorphs of 5-fluorocytosine. Acta Crystallogr C 65:o574-o578.
133. Ravindra NV, Panpalia GM, Jagarlapudi APS. 2009. Norfloxacin sesquihydrate. Acta Crystallogr E 65:o303.
134. Ng SW. 2009. A second monoclinic modification of triphenylphosphine oxide hemihydrate. Acta Crystallogr E 65:o1431.
135. Chernyshev VV, Machula AA, Kukushkin SY, Velikodny YA. 2009. Carvedilol dihydrogen phosphate hemihydrate: A powder study. Acta Crystallogr E 65:o2020-o2021.
136. Seidel RW, Koleva BB. 2009. β-Cyclodextrin 10.41-hydrate. Acta Crystallogr E 65:o3162-o3163.
137. Heinz A, Strachan CJ, Gordon KC, Rades T. 2009. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy. J Pharm Pharmacol 61:971-988.
138. Wikström H, Kakidas C, Taylor LS. 2009. Determination of hydrate transition temperature using transformation kinetics obtained by Raman spectroscopy. J Pharm Biomed Anal 49:247-252.
139. Kamada K, Yoshimura S, Murata M, Murata H, Nagai H, Ushio H, Terada K. 2009. Characterization and monitoring of pseudo-polymorphs in manufacturing process by NIR. Int J Pharm 368:103-108.
140. Lehto P, Aaltonen J, Tenho M, Rantanen J, Hirvonen J, Tanninen VP, Peltonen L. 2009. Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid. J Pharm Sci 98:985-996.
141. Drebushchak TN, Chesalov YA, Boldyreva EV. 2009. A conformational polymorphic transition in the high-temperature ε-form of chlorpropamide on cooling: a new ε'-form. Acta Crystallogr B 65:770-781.
142. Renou L, Coste S, Cartigny Y, Petit M-N, Vincent C. 2009. Mechanism of hydration and dehydration of ciclopirox ethanolamine (1:1). Cryst Growth Des 9:3918-3927.
143. a (Activation Energy) as a Quantitative Indicator of Physical Stability of Indomethacin Solvates: Methanolate and Tertiary Butyl Alcohol Solvate. Cryst Growth Design 9:3359-3366.
144. Guguta C, van Eck ERH, de Gelder R. 2009. Structural insight into the dehydration and hydration behavior of naltrexone and naloxone hydrochloride: Dehydration-induced expansion versus contraction. Cryst Growth Des 9:3384-3395.
145. Malaj L, Censi R, Di Martino P. 2009. Mechanisms for dehydration of three sodium naproxen hydrates. Cryst Growth Des 9:2128-2136.
146. Zimmermann A, Tian F, Lopez de Diego H, Elema MR, Rantanen J, Müllertz A, Hovgaard L. 2009. Influence of the solid form of siramesine hydrochloride on its behavior in aqueous environments. Pharm Res 26:846-854.
147. Hasegawa G, Komasaka T, Bando R, Yoshihashi Y, Yonemochi E, Fujii K, Uekusa H, Terada K. 2009. Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form. Int J Pharm 369:12-18.
148. Wsicki J, Kozlenko DP, Pankov SE, Bilski P, Pajzderska A, Hancock BC, Medek A, Nawrocik W, Savenko BN. 2009. NMR search for polymorphic phase transformations in chlorpropamide form-A at high pressures. J Pharm Sci 98:1426-1437.
149. Wang K, Duan D, Wang R, Liu D, Tang L, Cui T, Liu B, Cui Q, Liu J, Zou B, Zou G. 2009. Pressure-induced phase transition in hydrogen-bonded supramolecular adduct formed by cyanuric acid and melamine. J Phys Chem B 113:14719-14724.
150. Johnstone RDL, Lennie AR, Parsons S, Pidcock E, Warren JE. 2009. Comparison of the effects of pressure on three layered hydrates: a partially successful attempt to predict a high-pressure phase transition. Acta Cryst B 65:731-748.
151. Gajda R, Katrusiak A, Crassous J. 2009. Pressure-controlled aggregation in carboxylic acids: A case study on the polymorphism of bromochlorofluoroacetic acid. Cryst Eng Comm 11:2668-2676.
152. Hédoux A, Paccou L, Guinet Y, Willart J-F, Descamps M. 2009. Using the low-frequency Raman spectroscopy to analyze the crystallization of amorphous indomethacin. Eur J Pharm Sci 38:156-164.
153. Rumondor ACF, Stanford LA, Taylor LS. 2009. Effects of polymer type and storage relative humidity on the kinetics of felodipine crystallization from amorphous solid dispersions. Pharm Res 26:2599-2606.
154. Zhang F, Aaltonen J, Tian F, Saville DJ, Rades T. 2009. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin. Eur J Pharm Biopharm 71:64-70.
155. Strydom S, Liebenberg W, Yu L, de Villiers M. 2009. The effect of temperature and moisture on the amorphous-to-crystalline transformation of stavudine. Int J Pharm 379:72-81.
156. Moran A, Buckton G. 2009. Studies of the crystallization of amorphous trehalose using simultaneous gravimetric vapor sorption/near IR (GVS/NIR) and "modulated" GVS/NIR. AAPS PharmSciTech 10:297-302.
157. Petrova RI, Peresypkin A, Mortko CJ, McKeown AE, Lee J, Williams JM. 2009. Rapid conversion of API hydrates to anhydrous forms in aqueous media. J Pharm Sci 98:4111-4118.
158. Takada A, Nail SL, Yonese M. 2009. Subambient behavior of mannitol in ethanol-water co-solvent system. Pharm Res 26:568-576.
159. van Gyseghem E, Stokbroekx S, Novoa de Armas H, Dickens J, Vanstockem M, Baert L, Rosier J, Schueller L, Van Den Mooter G. 2009. Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 38:489-497.
160. Cornel J, Lindenberg C, Mazzotti M. 2009. Experimental characterization and population balance modeling of the polymorph transformation of L-glutamic acid. Cryst Growth Des 9:243-252.
161. Howard KS, Nagy ZK, Saha B, Robertson AL, Steele G, Martin D. 2009. A process analytical technology based investigation of the polymorphic transformations during the antisolvent crystallization of sodium benzoate from IPA/water mixture. Cryst Growth Des 9:3964-3975.
162. Coles SJ, Gelbrich T, Griesser UJ, Hursthouse MB, Pitak M, Threlfall T. 2009. The elusive high temperature solid-state structure of D, L-norleucine. Cryst Growth Des 9:4610-4612.
163. Minkov VS, Tumanov NA, Kolesov BA, Boldyreva EV, Bizyaev SN. 2009. Phase transitions in the crystals of L- and DL-cysteine on cooling: The role of the hydrogen-bond distortions and the side-chain motions. 2. DL-cysteine. J Phys Chem B 113:5262-5272.
164. Zencirci N, Gstrein E, Langes C, Griesser UJ. 2009. Temperature- and moisture-dependent phase changes in crystal forms of barbituric acid. Thermochim Acta 485:33-42.
165. Cheung EY, Peterson ML. 2009. Reconciling thermal and structural data from the polymorphic transitions of malonamide. Thermochim Acta 482:57-61.
166. Polaske NW, Nichol GS, Olenyuk B. 2009. Polymorphism and phase transition behavior of 6, 6'-bis(chloromethyl)-1, 1', 4, 4'-tetramethyl-3, 3'-(p-phenylenedimethylene) bis(piperazine-2, 5-dione). Acta Crystallogr C 65:o381-o384.
167. Ha J-M, Young V. 2009. Enantiotropic phase transition and twinning in 2, 2, 3, 3, 4, 4-hexafluoropentane-1, 5-diol. Acta Crystallogr C 65:o388-o395.
168. Jørgensen AC, Strachan CJ, Pöllänen KH, Koradia V, Tian F, Rantanen J. 2009. An insight into water of crystallization during processing using vibrational spectroscopy. J Pharm Sci 98: 3903-3932.
169. Gift AD, Luner PE, Luedeman L, Taylor LS. 2009. Manipulating hydrate formation during high shear wet granulation using polymeric excipients. J Pharm Sci 98:4670-4683.
170. Varasteh M, Deng A, Hwang H, Kim YJ, Wong GB. 1990. Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS® formulation. Int J Pharm 366:74-81.
171. Feng T, Bates S, Carvajal MT. 2009. Toward understanding the evolution of griseofulvin crystal structure to a mesophase after cryogenic milling. Int J Pharm 367:16-19.
172. Miyazaki T, Sivaprakasam K, Tantry J, Suryanarayanan R. 2009. Physical characterization of dibasic calcium phosphate dihydrate and anhydrate. J Pharm Sci 98:905-916.
173. Sun C. 2009. Improving powder flow properties of citric acid by crystal hydration. J Pharm Sci 98:1744-1749.
174. Varshney DB, Sundaramurthi P, Kumar S, Shalaev EY, Kang S-W, Gatlin LA, Suryanarayanan R. 2009. Phase transitions in frozen systems and during freeze-drying: Quantification using synchrotron X-Ray diffractometry. Pharm Res 26:1596-1606.
175. Takada A, Nail SL, Yonese M. 2009. Influence of ethanol on physical state of freeze-dried mannitol. Pharm Res 26:1112-1120.
176. Dixon D, Tchessalov S, Barry A, Warne N. 2009. The impact of protein concentration on mannitol and sodium chloride crystallinity and polymorphism upon lyophilization. J Pharm Sci 98:3419-3429.
177. Aronhime J, Lidor-Hadas R, Niddam V, Lifshitz R, Wizel S. 2009. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms. Patent US7, 488, 750.
178. Tessler L, Aronhime J, Lifshitz-Liron R, Maidan-Hanoch D, Hasson N. 2009. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms. Patent US7, 501, 450.
179. Van Der Schaaf PA, Blatter F, Szelagiewicz M, Schoning K-U. 2009. Crystalline forms of atorvastatin. Patent US7, 538, 136.
180. Leigh S, Leigh MLS, van Hoogevest P. 2009. Crystal forms of astaxanthin. Patent US7, 563, 935.
181. Aronhime J, Bianchi S, Castelli E, Daverio P, Mantovani S, Kovacsne-Mezei A. 2009. Polymorphs of atomoxetine hydrochloride. Patent US7, 473, 804.
182. Zenoni M, Cattaneo AG. 2009. Crystalline solvate of cefuroxime acid. Patent US7, 615, 631.
183. Hildesheim J, Finogueev S, Aronhime J, Dolitzky B-Z, Ben-Valid S, Kor I. 2009. Carvedilol. Patent US7, 485, 663.
184. Kor I, Wizel S. 2009. Crystalline solids of carvedilol and processes for their preparation. Carvedilol. Patent US7, 514, 467.
185. Kor I, Wizel S. 2009. Crystalline solids of carvedilol and processes for their preparation. Patent US7, 598, 396.
186. Hildesheim J, Fine S, Aronhime J, Dolitzky B-Z, Ben-Valid S, Kor-Sade I. 2009. Carvedilol. Patent US7, 605, 274.
187. Bedna R, Cvak L, Jegorov A, Sobotik R. 2009. Polymorphs of cabergoline. Patent US7, 531, 551.
188. Parthasaradhi RB, Rathnakar RK, Raji RR, Muralidhara RD, Subash-Chander RK. 2009. Crystalline forms of candesartan cilexetil. Patent US7, 504, 516.
189. Ferro LJ, Miyake PS. 2009. Polymorphic crystalline forms of celecoxib. Patent US7, 476, 744.
190. Parthasaradhi RB, Rathnakar RK, Raji RR, Muralidhara RD, Subash-Chander RK. 2009. Crystalline forms of donepezil hydrochloride. Patent US7, 560, 560.
191. Eisen-Nevo H, Maidan-Hanoch D. 2009. Drying process for preparing crystalline solid famciclovir. Patent US7, 473, 780.
192. Tanoury GJ, Senanayaka CH, Kessler DW. 2009. Formoterol tartrate process and polymorph. Patent US7, 479, 572.
193. Eiermann U, Junghans B, Knipp B, Sattelkau T. 2009. Ibandronate polymorph. Patent US7, 582, 789: September 1, 2009.
194. Merli V, Mantovani S, Bianchi S, Daverio P, Spreafico A, Aronhime J, Kovacsne-Mezei A. 2009. Levalbuterol hydrochloride polymorph B. Patent US7, 488, 758.
195. Niddam-Hildesheim V, Gershon N, Amir E, Wizel S. 2009. Preparation of levofloxacin and hemihydrate thereof. Patent US7, 629, 458.
196. Calderon A, Cox DP, Cyr PT, Park A. 2009. Oxycodone polymorphs. Patent US7, 534, 888.
197. Wizel S, Finogueev S, Hildesheim J. 2009. Pioglitazone hydrochloride. Patent US7, 517, 993.
198. Rao MA, Kuduva SS, Shreenivas MT. 2009. Polymorph of quetiapine fumarate and a process for its preparation. Patent US7, 488, 821.
199. Chou J-H, Gentzler MB, Michaels JN, Bazin C, Clas S-D, Dalton C, Wu MG. 2009. Polymorphic form of montelukast sodium. Patent US7, 560, 559.
200. Frenkel G, Gome B, Wizel S. 2009. Crystalline form of nateglinide. Patent US7, 534, 913.
201. Finkelstein N, Krochmal B, Wizel S, Braude V. 2009. Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates. Patent US7, 507, 829.
202. Viscomi GG, Campana M, Braga D, Confortini D, Cannata V, Righi P, Rosini G. 2009. Polymorphic forms α, β, and γ of rifaximin. Patent US7, 612, 199.
203. Divvela SRVN, Racha L, Meenakshisunderam S, Dandala R. 2009. Process for the preparation of risedronate sodium hemi-pentahydrate. Patent US7, 485, 726.
204. Reddy BP, Reddy KR, Reddy RR, Reddy DM, Reddy KSC. 2009. Processes for preparing sertraline hydrochloride crystalline forms. Patent US7, 518, 019.
205. Singh GP, Rawat GS, Dhake VN, Nehate SP. 2009. Crystalline form for quinapril hydrochloride and process for preparing the same. Patent US7, 482, 361.
206. Aihara K, Hasegawa T, Kitahara S, Watanabe T, Ando T, Sawabe T, Shitara E, Atsumi K, Ota K. 2009. Crystalline carbapenem intermediate. Patent US7, 482, 445.
207. Reddy MS, Rajan ST, Rao MVNB, Vyas K, Reddy SV, Rekha KS. 2009. Polymorphic form of 17-β-(N-t-butyl carbamoyl)-4-aza-5-α-androst-1-en-3-one. Patent US7, 501, 515.
208. Blythe T, Vlahova P. 2009. Polymorphic forms of (S)-1-cyanobutan-2-yl-(S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)-ureido)phenyl) ethylcarbamate. Patent US7, 504, 515.
209. Allen DJM, Norris T, Raggon JW, Santafianos DP, Shanker RM. N-(3-ethynylphenyl)-6, 7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate. Patent US7, 521, 456: April 21, 2009.
210. Yamamoto E. 2009. Crystal of two-ring heterocyclic sulfonamide compound. Patent US7, 521, 472.
211. Chao RS, Rapta M, Colson P-J. 2009. Crystalline form of a biphenyl compound. Patent US7, 521, 558.
212. Li L, Chao R, Hughes A, Ji Y-H, Khossravi D, Zhang W. 2009. Crystalline form of a substituted pyrrolidine compound. Patent US7, 524, 880.
213. Deshpande PK, Bhavsar SB, Chugh Y, Yeole RD, de Souza NJ, Patel MV. 2009. Polymorphs of racemic, dextrorotatory, and levorotatory enantioners of 1-cyclopropyl-6-fluoro-8-methoxy-7-(4-amino-3, 3-dimethylpiperidin-1-yl)-1-, 4-dihydro-4-oxo-quinoline-3-carboxylic acid hydrochloride and mesylate salts. Patent US7, 538, 221.
214. Hu Y, Phares KR, Law D. 2009. Polymorphic and other crystalline forms of cis-FTC. Patent US7, 544, 692.
215. Jungles S, Henderson MA, Sluzky V, Baffi R. 2009. Stable tablet formulation. Patent US7, 566, 462.
216. Dumic M, Vinkovic M, Oresic M, Mestrovic E, Danilovski A, Dumbovic A, Knezevic Z, Lazarevski G, Cincic D, Filic D, Lazaric K, Bucar DK. 2009. Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A. Patent US7, 569, 549.
217. Bush JKay, Reutzel-Edens SM. 2009. Salt and crystalline forms of (2R)-anti-5-{3-[4-(10, 11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline. Patent US7, 582, 762.
218. Biggadike K, Coote SJ, Craig A, Crowe DM, Jacewicz VW, Millan MJ, Nice RK, Noga B, Seager JF, Theophilus AL. 2009. Crystalline complexes of fluticasone-2-furoate. Patent US7, 592, 329.
219. Deshmukh SS, Ali K, Diorio CR, Ehrnsperger EC, Fawzi MB, Shah SM, Mirmehrabi M. 2009. Glucuronate salt of a piperazine compound. Patent US7, 595, 3102009.
220. Bougaret J, Avan J-L, Segonds R. 2009. Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof. Patent US7, 595, 335.
221. Blythe T, Eberlin A, Hurrey M, Jonaitis D, Nyce P, Parent S, Snoonian J. 2009. Polymorphic forms of (S)-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl) phenyl) ureido) benzylcarbamate. Patent US7, 605, 270.
222. Gilday JP. 2009. Crystalline forms of the anti-cancer compound ZD1839. Patent US7, 612, 077.
223. Orjales VA, Bordell MM, Canal MG, Blanco FH, de Pablo ML, Rubio RV, Mosquera PR. 2009. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-α, -α-dimethyl-benzeneacetic acid. Patent US7, 612, 095.
224. Akai J, Nishida H. 2009. Crystals of quinolinecarboxylic acid derivative solvate. Patent US7, 612, 205.
225. Matsushima T, Nakamura T, Yoshizawa K, Kamada A, Ayata Y, Suzuki N, Arimoto I, Sakaguchi T, Gotoda M. 2009. Crystalline form of the salt of 4-(3-chloro-4-(cyclo-propylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli-necarboxamide or the solvate of the salt and a process for preparing the same. Patent US7, 612, 208.
226. Amino Y, Hirasawa K. 2009. Organic amine salts of glutamic acid derivatives and their application. Patent US7, 612, 214.
227. Richter J, Jirman J, Petrickova H. 2009. Amorphous forms of risedronate monosodium. Patent US7, 618, 953.
228. Xu F, Gallop MA, Sasikumar V, Dilip U. 2009. Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof. Patent US7, 619, 110.
229. Lodaya RM. 2009. Crystalline ACAT inhibitor. Patent US7, 622, 610.
230. Huang L. 2009. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion. Patent US7, 625, 911.
231. Carter PH, Duncia JV, Mudryk BM, Randazzo ME, Xiao Z, Yang MG, Zhao R. 2009. N-((1R, 2S, 5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process. Patent US7, 629, 351.
232. Peterson M. 2009. Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate. Patent US7, 632, 963.